Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibudilast - MediciNova

Drug Profile

Ibudilast - MediciNova

Alternative Names: AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos

Latest Information Update: 24 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Banyu; Kyorin Pharmaceutical; MediciNova; National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Senju Pharmaceutical; University of California at Los Angeles; University of Colorado at Boulder; University of New South Wales
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antiallergics; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antiplatelets; Drug withdrawal therapies; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Astrocyte inhibitors; Cytokine modulators; Glial cell modulators; Leukotriene receptor antagonists; Macrophage migration inhibitory factor inhibitors; Nitric oxide synthase inhibitors; Phosphodiesterase 10A inhibitors; Phosphodiesterase 11A inhibitors; Toll-like receptor 4 antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Amyotrophic lateral sclerosis; Globoid cell leukodystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alcoholism; Drug abuse; Neurological disorders; Opioid abuse

Highest Development Phases

  • Marketed Allergic conjunctivitis; Asthma; Cerebrovascular disorders
  • Phase II Alcoholism; Amyotrophic lateral sclerosis; Drug abuse; Multiple sclerosis; Opioid abuse
  • Phase I/II Glioblastoma
  • Preclinical Globoid cell leukodystrophy
  • Suspended Neuropathic pain
  • No development reported Brain injuries; Headache
  • Discontinued Diabetic neuropathies; Diabetic retinopathy

Most Recent Events

  • 21 Jan 2019 MediciNova has patent protection for ibudilast as monotherapy for the treatment of Amyotrophic lateral sclerosis (ALS) in USA
  • 21 Jan 2019 MediciNova receives patent allowance for ibudilast for use in combination with riluzole for the treatment of amyotrophic lateral sclerosis in USA
  • 31 Dec 2018 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT03782415)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top